\"Dying to Survive\"’s box office revenue exceeds 300 million – thoughts on generic drugs for the instrumentation industry

Thread Content

　　Recently, a movie has been dominating social media feeds. \"Dying to Survive\" ignited the summer season of 2018 and brought tears to many people’s eyes. It has a rating of 9.0 on Douban, making it the top topic of discussion. According to CatEye data, as of the evening of July 5, the movie \"Dying to Survive\" had earned over 300 million yuan at the box office, achieving both massive box office success and high critical acclaim. http://www.jiweimeter.com/uploads/image/20180706/1530875983.jpg “Dying to Survive” is a realistic film based on true events. It boldly addresses sensitive topics such as healthcare and medicine, focuses on a special group from a unique perspective, and tells the story behind the reform of generic drugs in China – namely, how the owner of a health product store, played by Xu Zheng, procured Indian generic drugs for patients with terminal illnesses. 　　Behind every seemingly absurd and unrestrained story, there is an inevitable logic. The original branded drugs have been approved, but they are too expensive for you to afford ； Generic drugs are prohibited from being sold without approval ； If you’re sick, you need to take medicine; without it, you can only wait to die. This is where the intense conflict between reality and hope, law and morality lies in the movie. In real life, this incident caused a sensation in society and indirectly promoted the development of generic drugs in our country. 　　A generic drug, in essence, is a copy that is identical to the original drug in terms of dosage, safety and efficacy, mechanism of action, and indications. Due to the long development cycle, high costs, and expensive prices of original drugs, economically viable generic drugs have emerged and developed, leading to an increasing scale of this industry. 　　In recent years, population growth, an increasing aging population, and heightened public awareness of health have accelerated the development of the pharmaceutical market. Companies in India, South America, and other regions that produce generic drugs are entering the global market at low prices, and our country is also increasingly encouraging domestic enterprises and research institutions to boost the development of generic drugs. 　　On the other hand, data shows that by 2025, 48 core patents for imported chemical drugs in China will expire. When the patents on some imported foreign drugs expire or they withdraw from the market, this creates new opportunities for domestic generic drug manufacturers. 　　Adhering to the principle of giving equal emphasis to the development of new drugs and generic drugs, China strives to achieve a balance between the right to health and pharmaceutical intellectual property rights. The consistency assessment represents the requirements imposed on generic drugs at a **specific level**; the quality of such drugs must be consistent with that of the original branded drugs in the regulated market. Supported by policies such as the \"Opinions on Conducting Assessments of the Quality and Efficacy Consistency of Generic Drugs\" and the \"Opinions on Reforming and Improving Policies for the Supply and Use of Generic Drugs,\" the substitution of imported original drugs with domestic alternatives has been accelerated, thereby improving the quality of generic drugs. 　　Focusing on the instrumentation industry, the traditional models of innovation and development must be updated to keep pace with the times. Only enterprises that produce to truly meet societal needs can achieve long-term success. It is something that companies should consider: how to produce domestically-made instruments that are inexpensive yet of high quality, while simultaneously introducing advanced technologies and high-quality products from foreign brands. 　　From the perspective of supply and demand, increase investment in technology research and development, focusing on those segments of laboratory equipment for which there is a strong market demand but a shortage of supply ； Quantitative changes lead to qualitative changes; by seizing every market opportunity, the brand will develop step by step ； With continuous support at the policy level, the laws, regulations, innovative solutions, and standard methods in the instrumentation industry will become more comprehensive and thorough. Instrument manufacturers should keep an eye on industry trends, take on social responsibilities, and move forward in step with **development.